Overview

Dr. Anglesio's research has focused primarily on defining subtypes of ovarian cancer. In particular, genomic and protein-based biomarker studies that differentiate types and subtypes of each ovarian cancer histology. Most recently he has been focused on uncovering the mechanism through which endometriosis may become malignant and progress into either clear cell or endometrioid ovarian cancer. In 2017 Dr. Anglesio's group was first to provide evidence that roughly 1/3 of endometriosis frequently harbours cancer-driver mutations, and that these mutations are restricted to only one of two cell types that make up endometriosis.

Publications

You won't believe this old test … that does cheap single-cell mutation detection
The Journal of Pathology: Clinical Research
Martin Köbel and Michael S. Anglesio and James D. Brenton
DOI: 10.1002/cjp2.108
07/2018

Extrauterine high-grade serous carcinomas with bilateral adnexal involvement as the only two disease sites are clonal based on tp53 sequencing results: implications for biology, classification, and staging
Modern Pathology
Naveena Singh and Asma Faruqi and Friedrich Kommoss and W Glenn McCluggage and Giorgia Trevisan and Janine Senz and Amy Lum and C Blake Gilks and Michael Anglesio
DOI: 10.1038/modpathol.2017.159
04/2018

Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes
Nature Genetics
Yi Kan Wang and Ali Bashashati and Michael S Anglesio and Dawn R Cochrane and Diljot S Grewal and Gavin Ha and Andrew McPherson and Hugo M Horlings and Janine Senz and Leah M Prentice and Anthony N Karnezis and Daniel Lai and Mohamed R Aniba and Allen W Zhang and Karey Shumansky and Celia Siu and Adrian Wan and Melissa K McConechy and Hector Li-Chang and Alicia Tone and Diane Provencher and Manon de Ladurantaye and Hubert Fleury and Aikou Okamoto and Satoshi Yanagida and Nozomu Yanaihara and Misato Saito and Andrew J Mungall and Richard Moore and Marco A Marra and C Blake Gilks and Anne-Marie Mes-Masson and Jessica N McAlpine and Samuel Aparicio and David G Huntsman and Sohrab P Shah
DOI: 10.1038/ng.3849
06/2017

Recurrent DICER1 Hotspot Mutations in Endometrial Tumours And Their Impact on MicroRNA Biogenesis.
Chen J and Wang Y and McMonechy MK and Anglesio MS and Yang W and Senz J and Maines-Bandiera S and Rosner J and Trigo-Gonzalez G and Grace Cheng SW and Kim J and Matzuk MM and Morin GB and Huntsman DG
PubMed: 26033159
06/2015

Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden.
Anglesio MS and Bashashati A and Wang YK and Senz J and Ha G and Yang W and Aniba MR and Prentice LM and Farahani H and Li Chang H and Karnezis AN and Marra MA and Yong PJ and Hirst M and Gilks B and Shah SP and Huntsman DG
DOI: 10.1002/path.4516
PubMed: 25692284
06/2015

Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition.
Davis SJ and Sheppard KE and Anglesio MS and George J and Traficante N and Fereday S and Intermaggio MP and Menon U and Gentry-Maharaj A and Lubinski J and Gronwald J and Pearce CL and Pike MC and Wu A and Kommoss S and Pfisterer J and du Bois A and Hilpert F and Ramus SJ and Bowtell DD and Huntsman DG and Pearson RB and Simpson KJ and Campbell IG and Gorringe KL
DOI: 10.1158/1535-7163.MCT-15-0039
PubMed: 25852062
06/2015

Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
Mackenzie R and Kommoss S and Winterhoff BJ and Kipp BR and Garcia JJ and Voss J and Halling K and Karnezis A and Senz J and Yang W and Prigge ES and Reuschenbach M and Doeberitz MV and Gilks BC and Huntsman DG and Bakkum-Gamez J and McAlpine JN and Anglesio MS
DOI: 10.1186/s12885-015-1421-8
PubMed: 25986173
2015

Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study.
Köbel M and Madore J and Ramus SJ and Clarke BA and Pharoah PD and Deen S and Bowtell DD and Odunsi K and Menon U and Morrison C and Lele S and Bshara W and Sucheston L and Beckmann MW and Hein A and Thiel FC and Hartmann A and Wachter DL and Anglesio MS and Høgdall E and Jensen A and Høgdall C and Kalli KR and Fridley BL and Keeney GL and Fogarty ZC and Vierkant RA and Liu S and Cho S and Nelson G and Ghatage P and Gentry-Maharaj A and Gayther SA and Benjamin E and Widschwendter M and Intermaggio MP and Rosen B and Bernardini MQ and Mackay H and Oza A and Shaw P and Jimenez-Linan M and Driver KE and Alsop J and Mack M and Koziak JM and Steed H and Ewanowich C and DeFazio A and Chenevix-Trench G and Fereday S and Gao B and Johnatty SE and George J and Galletta L and AOCS Study Group and Goode EL and Kjær SK and Huntsman DG and Fasching PA and Moysich KB and Brenton JD and Kelemen LE
DOI: 10.1038/bjc.2014.567
PubMed: 25349970
12/2014

Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
Emmanuel C and Chiew YE and George J and Etemadmoghadam D and Anglesio MS and Sharma R and Russell P and Kennedy C and Fereday S and Hung J and Galletta L and Hogg R and Wain GV and Brand A and Balleine R and MacConaill L and Palescandolo E and Hunter SM and Campbell I and Dobrovic A and Wong SQ and Do H and Clarke CL and Harnett PR and Bowtell DD and deFazio A and Australian Ovarian Cancer Study (AOCS)
DOI: 10.1158/1078-0432.CCR-14-1292
PubMed: 25316818
12/2014

Harnessing the potential of lipid-based nanomedicines for type-specific ovarian cancer treatments.
Leung AW and Kalra J and Santos ND and Bally MB and Anglesio MS
DOI: 10.2217/nnm.13.220
PubMed: 24746193
03/2014

A current perspective on the pathological assessment of FOXL2 in adult-type granulosa cell tumours of the ovary.
Kommoss S and Gilks CB and Penzel R and Herpel E and Mackenzie R and Huntsman D and Schirmacher P and Anglesio M and Schmidt D and Kommoss F
DOI: 10.1111/his.12253
PubMed: 24192202
02/2014

A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.
Wiegand KC and Hennessy BT and Leung S and Wang Y and Ju Z and McGahren M and Kalloger SE and Finlayson S and Stemke-Hale K and Lu Y and Zhang F and Anglesio MS and Gilks B and Mills GB and Huntsman DG and Carey MS
DOI: 10.1186/1471-2407-14-120
PubMed: 24559118
2014

Accelerating type-specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high-throughput tool for case review.
Kommoss S and Gilks CB and Kommoss F and Chow C and Hilpert F and du Bois A and Köbel M and Huntsman DG and Anglesio M and Kalloger SE and Pfisterer J
DOI: 10.1111/his.12219
PubMed: 24033430
11/2013

Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling.
Bashashati A and Ha G and Tone A and Ding J and Prentice LM and Roth A and Rosner J and Shumansky K and Kalloger S and Senz J and Yang W and McConechy M and Melnyk N and Anglesio M and Luk MT and Tse K and Zeng T and Moore R and Zhao Y and Marra MA and Gilks B and Yip S and Huntsman DG and McAlpine JN and Shah SP
DOI: 10.1002/path.4230
PubMed: 23780408
09/2013

Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.
Sieh W and Köbel M and Longacre TA and Bowtell DD and deFazio A and Goodman MT and Høgdall E and Deen S and Wentzensen N and Moysich KB and Brenton JD and Clarke BA and Menon U and Gilks CB and Kim A and Madore J and Fereday S and George J and Galletta L and Lurie G and Wilkens LR and Carney ME and Thompson PJ and Matsuno RK and Kjær SK and Jensen A and Høgdall C and Kalli KR and Fridley BL and Keeney GL and Vierkant RA and Cunningham JM and Brinton LA and Yang HP and Sherman ME and García-Closas M and Lissowska J and Odunsi K and Morrison C and Lele S and Bshara W and Sucheston L and Jimenez-Linan M and Driver K and Alsop J and Mack M and McGuire V and Rothstein JH and Rosen BP and Bernardini MQ and Mackay H and Oza A and Wozniak EL and Benjamin E and Gentry-Maharaj A and Gayther SA and Tinker AV and Prentice LM and Chow C and Anglesio MS and Johnatty SE and Chenevix-Trench G and Whittemore AS and Pharoah PD and Goode EL and Huntsman DG and Ramus SJ
DOI: 10.1016/S1470-2045(13)70253-5
PubMed: 23845225
08/2013

FOXL2 molecular testing in ovarian neoplasms: diagnostic approach and procedural guidelines.
Kommoss S and Anglesio MS and Mackenzie R and Yang W and Senz J and Ho J and Bell L and Lee S and Lorette J and Huntsman DG and Blake Gilks C
DOI: 10.1038/modpathol.2012.226
PubMed: 23348906
06/2013

Cancer-associated somatic DICER1 hotspot mutations cause defective miRNA processing and reverse-strand expression bias to predominantly mature 3p strands through loss of 5p strand cleavage.
Anglesio MS and Wang Y and Yang W and Senz J and Wan A and Heravi-Moussavi A and Salamanca C and Maines-Bandiera S and Huntsman DG and Morin GB
DOI: 10.1002/path.4135
PubMed: 23132766
02/2013

Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.
Anglesio MS and Kommoss S and Tolcher MC and Clarke B and Galletta L and Porter H and Damaraju S and Fereday S and Winterhoff BJ and Kalloger SE and Senz J and Yang W and Steed H and Allo G and Ferguson S and Shaw P and Teoman A and Garcia JJ and Schoolmeester JK and Bakkum-Gamez J and Tinker AV and Bowtell DD and Huntsman DG and Gilks CB and McAlpine JN
DOI: 10.1002/path.4088
PubMed: 22899400
01/2013

Markers of T cell infiltration and function associate with favorable outcome in vascularized high-grade serous ovarian carcinoma.
Townsend KN and Spowart JE and Huwait H and Eshragh S and West NR and Elrick MA and Kalloger SE and Anglesio M and Watson PH and Huntsman DG and Lum JJ
DOI: 10.1371/journal.pone.0082406
PubMed: 24376535
2013

Correction: Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research.
Anglesio MS and Wiegand KC and Melnyk N and Chow C and Salamanca C and Prentice LM and Senz J and Yang W and Spillman MA and Cochrane DR and Shumansky K and Shah SP and Kalloger SE and Huntsman DG
2013

Correction: Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research.
Anglesio MS and Wiegand KC and Melnyk N and Chow C and Salamanca C and Prentice LM and Senz J and Yang W and Spillman MA and Cochrane DR and Shumansky K and Shah SP and Kalloger SE and Huntsman DG
PubMed: 24116245
2013

Type-specific cell line models for type-specific ovarian cancer research.
Anglesio MS and Wiegand KC and Melnyk N and Chow C and Salamanca C and Prentice LM and Senz J and Yang W and Spillman MA and Cochrane DR and Shumansky K and Shah SP and Kalloger SE and Huntsman DG
DOI: 10.1371/journal.pone.0072162
PubMed: 24023729
2013

The autophagy protein LC3A correlates with hypoxia and is a prognostic marker of patient survival in clear cell ovarian cancer.
Spowart JE and Townsend KN and Huwait H and Eshragh S and West NR and Ries JN and Kalloger S and Anglesio M and Gorski SM and Watson PH and Gilks CB and Huntsman DG and Lum JJ
DOI: 10.1002/path.4090
PubMed: 22926683
12/2012

Cytokine gene expression signature in ovarian clear cell carcinoma.
Yanaihara N and Anglesio MS and Ochiai K and Hirata Y and Saito M and Nagata C and Iida Y and Takakura S and Yamada K and Tanaka T and Okamoto A
DOI: 10.3892/ijo.2012.1533
PubMed: 22751940
09/2012

LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin.
Cowin PA and George J and Fereday S and Loehrer E and Van Loo P and Cullinane C and Etemadmoghadam D and Ftouni S and Galletta L and Anglesio MS and Hendley J and Bowes L and Sheppard KE and Christie EL and Pearson RB and Harnett PR and Heinzelmann-Schwarz V and Friedlander M and McNally O and Quinn M and Campbell P and deFazio A and Bowtell DD and Australian Ovarian Cancer Study
DOI: 10.1158/0008-5472.CAN-12-0203
PubMed: 22896685
08/2012

Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers.
Heravi-Moussavi A and Anglesio MS and Cheng SW and Senz J and Yang W and Prentice L and Fejes AP and Chow C and Tone A and Kalloger SE and Hamel N and Roth A and Ha G and Wan AN and Maines-Bandiera S and Salamanca C and Pasini B and Clarke BA and Lee AF and Lee CH and Zhao C and Young RH and Aparicio SA and Sorensen PH and Woo MM and Boyd N and Jones SJ and Hirst M and Marra MA and Gilks B and Shah SP and Foulkes WD and Morin GB and Huntsman DG
DOI: 10.1056/NEJMoa1102903
PubMed: 22187960
01/2012

Benign serous ovarian tumour: a redefining moment?
Hunter S and Gorringe K and Anglesio M and Sharma R and Gilks B and deFazio A and Huntsman D and Campbell I
2012

Copy number aberrations in benign serous ovarian tumors: a case for reclassification?
Hunter SM and Anglesio MS and Sharma R and Gilks CB and Melnyk N and Chiew YE and deFazio A and Australian Ovarian Cancer Study Group and Longacre TA and Huntsman DG and Gorringe KL and Campbell IG
DOI: 10.1158/1078-0432.CCR-11-2080
PubMed: 21976534
12/2011

Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010.
Anglesio MS and Carey MS and Köbel M and Mackay H and Huntsman DG and Vancouver Ovarian Clear Cell Symposium Speakers
DOI: 10.1016/j.ygyno.2011.01.005
PubMed: 21276610
05/2011

Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas.
McConechy MK and Anglesio MS and Kalloger SE and Yang W and Senz J and Chow C and Heravi-Moussavi A and Morin GB and Mes-Masson AM and Australian Ovarian Cancer Study Group and Carey MS and McAlpine JN and Kwon JS and Prentice LM and Boyd N and Shah SP and Gilks CB and Huntsman DG
DOI: 10.1002/path.2848
PubMed: 21381030
04/2011

IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.
Anglesio MS and George J and Kulbe H and Friedlander M and Rischin D and Lemech C and Power J and Coward J and Cowin PA and House CM and Chakravarty P and Gorringe KL and Campbell IG and Australian Ovarian Cancer Study Group and Okamoto A and Birrer MJ and Huntsman DG and de Fazio A and Kalloger SE and Balkwill F and Gilks CB and Bowtell DD
DOI: 10.1158/1078-0432.CCR-10-3314
PubMed: 21343371
04/2011

Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers.
Helland Å and Anglesio MS and George J and Cowin PA and Johnstone CN and House CM and Sheppard KE and Etemadmoghadam D and Melnyk N and Rustgi AK and Phillips WA and Johnsen H and Holm R and Kristensen GB and Birrer MJ and Australian Ovarian Cancer Study Group and Pearson RB and Børresen-Dale AL and Huntsman DG and deFazio A and Creighton CJ and Smyth GK and Bowtell DD
DOI: 10.1371/journal.pone.0018064
PubMed: 21533284
2011

ARID1A mutations in endometriosis-associated ovarian carcinomas.
Wiegand KC and Shah SP and Al-Agha OM and Zhao Y and Tse K and Zeng T and Senz J and McConechy MK and Anglesio MS and Kalloger SE and Yang W and Heravi-Moussavi A and Giuliany R and Chow C and Fee J and Zayed A and Prentice L and Melnyk N and Turashvili G and Delaney AD and Madore J and Yip S and McPherson AW and Ha G and Bell L and Fereday S and Tam A and Galletta L and Tonin PN and Provencher D and Miller D and Jones SJ and Moore RA and Morin GB and Oloumi A and Boyd N and Aparicio SA and Shih IeM and Mes-Masson AM and Bowtell DD and Hirst M and Gilks B and Marra MA and Huntsman DG
DOI: 10.1056/NEJMoa1008433
PubMed: 20942669
10/2010

Profiling the cancer genome.
Cowin PA and Anglesio M and Etemadmoghadam D and Bowtell DD
DOI: 10.1146/annurev-genom-082509-141536
PubMed: 20590430
2010

Copy number analysis identifies novel interactions between genomic loci in ovarian cancer.
Gorringe KL and George J and Anglesio MS and Ramakrishna M and Etemadmoghadam D and Cowin P and Sridhar A and Williams LH and Boyle SE and Yanaihara N and Okamoto A and Urashima M and Smyth GK and Campbell IG and Bowtell DD and Australian Ovarian Cancer Study
DOI: 10.1371/journal.pone.0011408
PubMed: 20844748
2010

Are there any more ovarian tumor suppressor genes? A new perspective using ultra high-resolution copy number and loss of heterozygosity analysis.
Gorringe KL and Ramakrishna M and Williams LH and Sridhar A and Boyle SE and Bearfoot JL and Li J and Anglesio MS and Campbell IG
DOI: 10.1002/gcc.20694
PubMed: 19603523
10/2009

Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors.
Anglesio MS and Arnold JM and George J and Tinker AV and Tothill R and Waddell N and Simms L and Locandro B and Fereday S and Traficante N and Russell P and Sharma R and Birrer MJ and AOCS Study Group and deFazio A and Chenevix-Trench G and Bowtell DD
DOI: 10.1158/1541-7786.MCR-08-0193
PubMed: 19010816
11/2008

The E3 ligase HACE1 is a critical chromosome 6q21 tumor suppressor involved in multiple cancers.
Zhang L and Anglesio MS and O'Sullivan M and Zhang F and Yang G and Sarao R and Mai PN and Cronin S and Hara H and Melnyk N and Li L and Wada T and Liu PP and Farrar J and Arceci RJ and Sorensen PH and Penninger JM
DOI: 10.1038/nm1621
PubMed: 17694067
09/2007

Akt-mediated YB-1 phosphorylation activates translation of silent mRNA species.
Evdokimova V and Ruzanov P and Anglesio MS and Sorokin AV and Ovchinnikov LP and Buckley J and Triche TJ and Sonenberg N and Sorensen PH
DOI: 10.1128/MCB.26.1.277-292.2006
PubMed: 16354698
01/2006

Differential expression of a novel ankyrin containing E3 ubiquitin-protein ligase, Hace1, in sporadic Wilms' tumor versus normal kidney.
Anglesio MS and Evdokimova V and Melnyk N and Zhang L and Fernandez CV and Grundy PE and Leach S and Marra MA and Brooks-Wilson AR and Penninger J and Sorensen PH
DOI: 10.1093/hmg/ddh215
PubMed: 15254018
09/2004

Research

Influence of "cancer driver" somatic mutation on the immune microenvironment of endometriosis and endoemtriosis-associated ovarian cancers

Prevelance of "cancer driver" somatic mutations in endometriosis subtypes, as well as the association of somatic mutations with clinical factors such as pain

Grants

CIHR Early Career Investigator Operating Grant: Endometriosis Microenvironment: Influence of "Cancer-Driver" Mutations

NIH R37 Project Grant (Co-Applicant): High-throughput Epigenomic Mapping of Regulatory Elements in Ovarian Cancer at Basepair Resolution

CIHR Project Grant (Co-Pl): Sexual Pain in Endometriosis: Role of Somatic Mutations and Local Neurogenesis

Honours & Awards

2016/5 - Department of Pathology and Laboratory Medicine Award for Excellence in Mentoring, University of British Columbia

2019/1- Most impactful paper published in 2017 from the Columbia Hospital for Women Research Foundation (CHWRF) with reference to: Anglesio et al. N Eng J Med 2017. Cancer-Associated Mutations in Endometriosis without Cancer